Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease [5]

Bone Marrow Transplantation

Volumn 33, Issue 1, 2004, Pages 129-130

  Imashuku, S ^a,c   Teramura, T ^a   Morimoto, A ^b   Naya, M ^c   Kuroda, H ^c  

^a Kyoto City Institute of Health and Environmental Sciences   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c KYOTO CITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; RITUXIMAB;

ADULT; APLASTIC ANEMIA; ASPERGILLOSIS; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CASE REPORT; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; EPSTEIN BARR VIRUS; GRAFT VERSUS HOST REACTION; HUMAN; HYPOGAMMAGLOBULINEMIA; IMMUNOGLOBULIN BLOOD LEVEL; LETTER; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGAMMAGLOBULINEMIA; ANTIBODIES, MONOCLONAL; BONE MARROW TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE;

EID: 0742306740     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704307     Document Type: Letter

References (7)

1. Verschuuren EA, Stevens SJ, van Imhoff GW et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation 2002; 73: 100-104.
2. Quartier P, Brethon B, Philippet P et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2000; 358: 1511-1513.
3. Castagnola E, Dallorso S, Faraci M et al. Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-related post-transplant lymphoproliferative disease preemptive therapy. J Hematother Stem Cell Res 2003; 12: 9-10.
4. Imashuku S, Naya M, Tamura S et al. Effectiveness of rituximab for chemotherapy-resistant multiple tumoral B-LPD in a haematopoietic stem cell recipient. Br J Haematol 2002; 117: 771-773.
5. Faye A, Quartier P, Reguerre Y et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001; 115: 112-118.
6. van Esser JWJ, Niesters HGM, van der Holt B et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364-4369.
7. Kuehnle I, Huls MH, Liu Z et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem cell transplantation. Blood 2000; 95: 1502-1505.